Figure 2

H19 over-expression contributes to cisplatin resistance.
(A) miR-675-3p expression level in different tissue and different RFS patients samples; (B) miR-125b expression level in different tissue and different RFS patients samples; The statistic analysis of (A,B) was performed by t-test, two sided, equal variances not assumed. (C) Dynamic changes of H19 expression level in response to cisplatin treatment. The 1–8 time course successively present 0.5, 2, 8, 24 hours after cisplatin treatment and 2, 8, 24, 48 hours after medium replacement. (D) H19 and miR-675-3p expression level after H19 siRNA interference. (E) Toxicity sensitivity analysis of A2780-DR/H19si and A2780-DR/control cells under cisplatin treatment in 24 hours.